Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect Bio-Techne to post earnings of $0.38 per share and revenue of $285.84 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $289.46 million during the quarter, compared to analyst estimates of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.35 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

TECH stock opened at $74.60 on Wednesday. Bio-Techne has a twelve month low of $61.16 and a twelve month high of $85.57. The company has a quick ratio of 3.26, a current ratio of 4.56 and a debt-to-equity ratio of 0.14. The company has a market cap of $11.85 billion, a P/E ratio of 79.36, a price-to-earnings-growth ratio of 5.80 and a beta of 1.27. The business’s fifty day moving average is $74.58 and its 200-day moving average is $74.53.

Wall Street Analyst Weigh In

TECH has been the topic of a number of recent analyst reports. Scotiabank raised their target price on Bio-Techne from $83.00 to $88.00 and gave the stock a “sector outperform” rating in a report on Thursday, October 31st. Robert W. Baird lifted their price objective on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised shares of Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.00.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.